Cancer Institute A national cancer institute
designated cancer center

Technology and Biostatistical Development

CEP advances population science research through the development of novel biostatistical technologies and methods. A key aim of this work is to enable the high-volume processing of samples in a cost-effective and timely manner.

Much of this work has been facilitated by the Stanford Genome Technology Center. Center contributions include the development of the DNA microarray technology in 1989 and more recently, the development of the Modular Inversion Probe technology, which can perform high throughput multiplex quantitative assays (over 40,000 at this time). These assays include SNP detection, genome content, alternative splicing, microbial typing, DNA methylation, somatic mutation detection and protein detection, which is 104 times more sensitive than an ELISA and is being developed for early cancer detection.

In collaboration with colleagues at USC and other institutions, CEP researchers have also worked to develop and expand biostatistical methods for analyzing the complex data collected from large genetic epidemiology studies. For example, they have developed a computer program to estimate the power of genome-wide association studies that accommodates multiple testing issues.

Program Researchers

Ronald Davis, PhD

Alice Whittemore, PhD


Stanford Medicine Resources:

Footer Links: